secwatch.observer — SEC 8-K summary
======================================

Issuer:     GUIDED THERAPEUTICS INC (GTHP)
CIK:        0000924515
Form:       8-K
Filed at:   2021-09-07T23:59:59+00:00
Accession:  0001654954-21-009799
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 1.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Guided Therapeutics passes regulatory review in China; receives $133K payment from SMI
--------------------------------------------------------------------------------

- Clinical trial at Fudan University approved; trials at 4 centers start Q3 2021.
- SMI paid $133,000 first installment; total $510,635 due during study.
- Expected payments up to $3M by end 2022 if NMPA approval granted.
- Minimum orders of $72M over 4 years post Chinese FDA approval.
- LuViva disposable royalty set at $1.90 per unit, adjusted for inflation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/924515/000165495421009799/0001654954-21-009799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/924515/000165495421009799/gthp_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-21-009799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer